Innoviva Net Worth 2010-2024 | INVA

Interactive chart of historical net worth (market cap) for Innoviva (INVA) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. Innoviva net worth as of May 10, 2024 is $0.99B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.986B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $722.308B 104.40
Novo Nordisk (NVO) Denmark $576.289B 44.28
Johnson & Johnson (JNJ) United States $360.785B 14.33
Merck (MRK) United States $329.417B 59.94
AbbVie (ABBV) United States $283.863B 14.67
AstraZeneca (AZN) United Kingdom $239.292B 20.80
Novartis AG (NVS) Switzerland $208.692B 14.80
Pfizer (PFE) United States $158.721B 19.73
Sanofi (SNY) $124.659B 11.76